Paquinimod

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePaquinimod
Drug Alias Namepaquinimodum帕喹莫德ABR-215757SLE-57-5757-57
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionS100 calcium binding protein A9 inhibitors
TargetsS100 calcium binding protein A9
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenDenmarkGermany +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesActive Biotech Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesActive Biotech Ab
Active IndicationsN/A
Inactive IndicationsScleroderma, SystemicLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A